• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Panel: Your genome will be part of your electronic medical record

Panel: Your genome will be part of your electronic medical record

October 14, 2010 By Christian Holland

EMRs graphic

A major goal for genomics scientists is the integration of the gene into healthcare information technology.

"The vision, as we see it, is that the genome is really a component of the patient’s electronic medical record," said GenomeQuest acting CEO Richard Resnick during a panel discussion about the future of genetic science yesterday at Harvard Medical School’s World Health Forum in Boston.

GenomeQuest, a whole-genome analysis application developer, yesterday announced a collaboration with the Beth Israel Deaconess Medical Center’s pathology department. Under the program, the hospital’s doctors will have access to the company’s predictive medicine tools and will co-develop healthcare IT systems that include genomic information.

Healthcare IT is already heading in the direction of biomarker-based medicine, argued Scientia Advisors managing partner Harry Glorikian.

If a patient has positive or negative results for a particular test, there are already alarms built into healthcare IT applications that warn doctors about how certain treatments could affect the patient, Glorikian told MassDevice.

"If that’s not directing the practice of medicine, I don’t know what is," he said. "It’s supposed to be a guideline. It’s not etched in stone, but if you do something that it says you shouldn’t, ‘What was you medical rational for doing that?’" he asked.

There is also a shift in the development of drugs, according to Glorikian. Some drug companies are no longer searching for blockbuster drugs and have started to trend towards personalized medicine based on individual biomarkers.

The idea is that a patient has a certain biomarker and therefore a specific drug is appropriate for them, he said. Insurance companies are also changing their coverage of drugs based on their linkage to biomarkers, Glorikian added.

Drug companies’ decision to develop personalized pharmaceuticals is economically driven more than anything else, he said, mentioning Pfizer Inc. (NYSE:PFE), Novartis AG (NYSE:NVS), Eli Lilly & Co. (NYSE:LLY), Sanofi-Aventis SA (NYSE:SNY) and AstraZeneca plc (NYSE:AZN) as companies that have begun talking about it. They want to go after smaller, medium-sized markets so that they "don’t get slammed when something comes off patent, because that cliff is huge," Glorikian said.

The Food & Drug Administration has already approved more than 30 drugs with “biomarker guidelines for treatment,” according to Resnick.

"In the next two or three years, you’ll really see the proof in the pudding. Who’s actually doing what. Because it’s one thing to talk about it," said Glorikian. "It’s a little bit harder," and "doctors don’t like it, but if you look at the way health IT systems are being designed, that’s the direction it’s going," he said.

And that’s only the beginning. If the goal is to introduce genomic information into electronic health records, an entire industry — and a new set of ethical quandaries — are about to change the way healthcare is practiced.

"In the future, diagnostic tests will not be characterized by a set of reagents, but really software filters placed on whole genome data," Harvard Medical School biomedical informatics professor Dr. Mark Boguski told MassDevice.

"Rather than working on developing molecular diagnostics that are based on individual technology platforms a reagent sets, it will a common exercise in algorithm development and software filters placed on whole genome-transcriptive data. That’s what we’re going to be co-developing with Genomequest," he said.

Consumers can go directly to a company and get their genome sequenced.

"We feel we’re putting laboratory medicine specialists back in the loop, which is a good thing," Boguski said. "I think it’s going to be well received by the payors if patients are going out and getting their own genomes done and then showing up at their doctors office.

"If you integrate [that] into established workflows in clinical pathology, we don’t have to invent anything new to handle that. It’s just a question of working with the regulators to make sure their are adequate quality standards, that it’s all HIPAA-compliant and so forth," he said.

Filed Under: Genomics/Molecular Diagnostics, News Well, Software / IT Tagged With: GenomeQuest, Harvard Medical School

In case you missed it

  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • Enovis partners with Kelvi on hot and cold therapies
  • West Pharmaceutical Services debuts new needle syringe system
  • Titan Medical names Cary G. Vance as new president, CEO
  • Acutus completes first closing in left-heart access portfolio sale to Medtronic
  • FDA clears Intuitive, Siemens Healthineers imaging integration for robotic bronchoscopy
  • FDA backs COVID-19 boosters with BA.4/5 spike proteins for fall
  • How safe is health information after the overturning of Roe?
  • Smith+Nephew opens new plant in Malaysia
  • BD launches combination COVID-19, flu, RSV diagnostic test
  • Zimmer Biomet creates independent nonprofit organization to reduce health disparities
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
  • Nasdaq grants Titan Medical 180-day extension to regain compliance
  • Aerin Medical reports positive 4-year results for VivAer treatment
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
  • How medical device companies are responding to abortion bans

RSS From Medical Design & Outsourcing

  • Supply Chain EVP Greg Smith sees fewer suppliers in Medtronic’s future
    All eyes are on Medtronic’s global operations and supply chain leader as he works to modernize its operations and scrutinize suppliers. EVP of Global Operations and Supply Chain Greg Smith anticipates fewer suppliers in Medtronic’s future, he said in an interview this week. Smith spoke with DeviceTalks Editorial Director Tom Salemi in his first published… […]
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
    CeQur designed its Simplicity device to make insulin delivery as seamless as possible for people with diabetes. When it comes to managing diabetes, CeQur wants to make insulin therapy as convenient as possible. For those who prefer to manage their own insulin delivery, the Simplicity device might just do exactly that. Simplicity, a wearable, disposable… […]
  • Meddux opens new facility in Colorado
    Engineering, design, development and manufacturing company Meddux announced that it opened a new facility in Boulder, Colorado. The new, 22,000-square-foot facility doubles the overall square footage from its previous location in Colorado. According to a news release, it helps the company to quadruple its product development area and double its manufacturing footprint. Meddux’s new facility… […]
  • Reducing the Overall Cost of Validation
    By PTI Engineered Plastics Reliable medical devices and equipment are essential for researchers and doctors to accurately diagnose and treat a wide range of diseases. That is why there is such stringent oversight from the FDA to ensure these products meet the necessary requirements and specifications. To ensure compliance with regulators, manufacturers follow installation qualification… […]
  • BBS Automation has a deal to buy medtech supplier Kahle Automation
    BBS Automation said it plans to purchase high-speed automation supplier Kahle Automation to expand its medtech and life sciences business. Kahle will operate as Kahle – a BBS Company, according to a news release from Munich, Germany-based BBS and Lombardy, Italy-based Kahle. The deal is subject to regulatory approval. Terms were not disclosed. Kahle’s co-owners —… […]
  • How safe is health information after the overturning of Roe?
    The U.S. Department of Health and Human Services today issued guidance meant to better protect women’s health information as state abortion bans kick in after the U.S. Supreme Court’s overturning of Roe v. Wade. Despite the HHS actions, women may still wonder whether their health information is entirely safe going forward — a potential challenge… […]
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
    New evidence is showing that COVID-19 may increase a person’s risk of diabetes, but it could be years until we know for sure. In the meantime, Dexcom (Nasdaq:DXCM) is getting ready, VP of Global Clinical Initiatives Tomas Walker said. Walker recently spoke with Medical Design & Outsourcing to discuss the San Diego-based diabetes device developer’s… […]
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
    Blackrock Neurotech and the University of Pittsburgh’s Rehab Neural Engineering Labs (Pitt RNEL) are working together on the first portable brain-computer interface (BCI) to allow patients to participate in research trials from home. A Blackrock representative said it’s the final step as the company prepares to launch its first commercial product early next year. Salt… […]
  • How medical device companies are responding to abortion bans
    Days after the U.S. Supreme Court’s decision to overturn Roe v. Wade’s protection of abortion rights, medical device companies are among those reassuring workers about healthcare access. Corporate communications to employees and the public at large come as trigger laws in nearly half of the states outlaw abortion immediately. Some medtech companies are not using… […]
  • Philips updates on testing results for recalled ventilators
    Royal Philips (NYSE:PHG) says only a small portion of returned respiratory devices displayed the sound abatement foam degradation that sparked a massive recall. Repeated ozone cleaning may have made the problem worse. Those were some of the major takeaways from an update Philips provided today on a comprehensive test and research program it implemented after its… […]
  • ResMed names Lucile Blaise as new Sleep & Respiratory Care leader
    Lucile Blaise will be the new president of ResMed’s Sleep & Respiratory Care business starting July 1, ResMed (NYSE: RMD) said today. She replaces Jim Hollingshead, who became president and CEO of Insulet (Nasdaq:PODD) on June 1. ResMed President and COO Rob Douglas is serving as interim president of the Sleep & Respiratory Care during… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS